Report copyright - Bladder Cancer: In Which Scenario is Immunotherapy The ... · Atezolizumab 1200 mg IV Q3W until PD Atezolizumab 1200 mg IV Q3W until loss of benefit 1. ClinicalTrials.gov. NCT02108652
Please pass captcha verification before submit form